Testosterone Therapy and Cardiovascular Risk

- Advances and Controversies

Testosterone Therapy and Cardiovascular Risk - Advances and Controversies

Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM.
Testosterone therapy and cardiovascular risk: advances and controversies.
Mayo Clin. Proc. 2015;90(2):224-251.

One of the most debated issues related to testosterone therapy is its effects on cardiovascular risk, such as heart attack and stroke. This editorial summarizes key conclusions from a special review article written by the Androgen Study Group and published in Mayo Clinic Proceedings.1

Key Points

  • Low levels of total, bioavailable, and free testosterone are associated with increased risk of mortality from all causes and cardiovascular disease.
  • Incident coronary artery disease is associated with lower levels of total, bioavailable, or free testosterone.
  • Severity of coronary artery disease is inversely correlated with serum concentrations of total, bioavailable, or free testosterone.
  • Carotid intima-media thickness and/or carotid plaque volume are inversely correlated with levels of total, bioavailable, or free testosterone.
  • Testosterone therapy is associated with a significant reduction in obesity and fat mass.
  • Testosterone therapy is associated with small decreases in levels of total cholesterol, HDL, and LDL. No clear effect on triglycerides has been documented.
  • Testosterone therapy is associated with a decrease in serum glucose concentrations, HbA1c, and insulin resistance in both diabetic and prediabetic men.
  • Testosterone therapy is associated with an inconsistent reduction in serum concentrations of inflammatory markers.
  • Testosterone therapy improves time to onset of symptomatic angina with exercise.
  • Testosterone therapy improves exercise capacity and peak oxygen consumption in men with symptomatic congestive heart failure.
  • Available evidence is insufficient to conclude whether there exists a relationship between ischemic stroke and blood androgen levels.

What is known

Hypogonadism, also known as testosterone deficiency, is a clinical syndrome characterized by a set of signs and symptoms in combination with low testosterone levels.2,3 Symptoms include decreased libido, erectile dysfunction, difficulty achieving orgasm, reduced intensity of orgasm, fatigue, decreased energy, depressed mood, irritability, and decreased sense of well-being. Objective signs include anemia, decreased bone density, reduced muscle strength and mass, increased body fat mass (both visceral and total), and weight gain.2,3 Importantly, testosterone deficiency in older men is associated with increased risk of death over the following 20 years, independent of multiple traditional risk factors and several preexisting health conditions.4,5

The goal of treatment is to alleviate symptoms and signs by restoring testosterone concentrations to optimal levels within the physiological range. Established benefits of testosterone therapy in hypogonadal men include improved sexual desire and function6-9, improved energy, mood and vitality9-13, increased lean mass8,13-16, decreased waist circumference17-21, reduced total body fat mass13-16, and increased bone mineral density.22-25 Promising new data reveal that testosterone therapy improves insulin sensitivity26-28 and reduces blood glucose17,19,29 and HbA1c17,19,21,29 levels in men with type 2 diabetes or obesity.

Numerous studies have consistently demonstrated improvements in cardiovascular risk factors with testosterone therapy, such as body fat mass and obesity13-16, waist circumference21,27, and glycemic control.21,26,27 These findings may explain the frequently observed outcome of increased mortality among men with low testosterone levels.4,5,30-34

What this review adds

The purpose of the Mayo Clinic Proceedings paper was to address the key scientific question - is testosterone therapy associated with increased cardiovascular risks?1

An objective assessment of the medical research literature regarding testosterone and cardiovascular effects must include the large number of studies on testosterone deficiency and its consequences, as well as the effects of testosterone therapy on cardiovascular risk factors and clinical outcomes. The conclusions from this review are summarized in the key points above.

As part of a comprehensive analysis it is also important to scrutinize studies with seemingly contradictory results.

Recent controversial studies

Against the background of well-documented health benefits of testosterone therapy in hypogonadal men, established in clinical trials, the Androgen Study Group finds it surprising that publication of two retrospective studies reporting increased risks of cardiovascular adverse events would cause such great concern. In medical research, the retrospective study design is one of the lowest quality evidence.35,36

The first study, published in November 2013 by Vigen et al.37, reported increased rates of heart attacks, strokes, and deaths in men who received testosterone prescriptions compared with untreated men, using scrupulous statistical methodology that reversed the raw data which actually suggested that the percentage of adverse events in testosterone-treated men was lower, by half, compared with untreated men.38 Large data errors revealed post-publication led to a call for retraction by 29 medical societies.39

The second study, published in January 2014 by Finkle et al.40, reported an increased rate of heart attacks in the period up to 90 days following receipt of a testosterone prescription compared with the prior 12 months. However, the observed number of heart attacks among men who received a testosterone prescription was only one-third of the expected rate in the general population, and because of the absence of a control group of men who did not receive testosterone prescription, one cannot determine whether the reported heart attack events were higher, lower, or unchanged in association with a testosterone prescription.41

Although these 2 studies gained enormous media attention, neither provides credible evidence of increased risk, and they have undergone serious criticism in the scientific literature.39,41-43 The FDA itself commented on these studies, concluding that none provide compelling evidence of increased cardiovascular risk.44

Notable key effects of testosterone therapy in regards to cardiovascular risk

Supporting the conclusions from the review by the Androgen Study Group are two notable studies. The first of these showed a reduction in atherosclerosis (measured by carotid intima media thickness) among testosterone deficient men treated with testosterone.27 Interestingly, the greater the magnitude of the increase in testosterone levels with treatment, the greater the magnitude of atherosclerosis reduction.

The second study compared 54 weeks of diet and exercise alone versus diet and exercise plus testosterone treatment with intramuscular injections of testosterone undecanoate in obese hypogonadal men.45 Testosterone treatment resulted in significant reduction in atherosclerosis and improvement in heart function (measured by cardiac ejection fraction). Notably, cessation of testosterone therapy resulted in return of these health improvements to baseline 24 weeks later.45

These studies raise the possibility that restoring testosterone levels with testosterone therapy may actually reverse atherosclerosis in men who have testosterone deficiency.

Testosterone prescriptions

Prescription rates for testosterone products have increased substantially worldwide over the last decade.46-50 However, only 10% to 12% of hypogonadal patients are actually receiving testosterone treatment for their hypogonadism.51,52 The rise in testosterone prescriptions seems to have resulted from increased awareness of testosterone deficiency and the benefits of testosterone therapy among both physicians and patients, coupled with reduced concern regarding prostate cancer risk.53 With the wealth of evidence outlined in the Mayo Clinic review, now doctors and patients can put their fears about cardiovascular risks to rest as well.

Public health burden of hypogonadism

Notably, testosterone deficiency has been projected to be involved in the development of approximately 1.3 million new cases of cardiovascular disease, 1.1 million new cases of diabetes, and over 600,000 osteoporosis-related fractures.54 Over a 20-year period, T deficiency has been estimated to be directly responsible for approximately $190 to $525 billion in inflation-adjusted U.S. health care expenditures.54 In line with this, longitudinal models predict increased outpatient visits and costs from low baseline serum testosterone levels independent of socio-economic and lifestyle factors; even when controlling for age, men aged 20 - 79 years at baseline with low serum testosterone levels had 29% more outpatient visits and 38% higher outpatient costs after a 5-year follow up.55

Summary

A wealth of modern data accumulated over the last two decades has demonstrated that a low testosterone level is associated with increased risk of development of cardiovascular risk factors, atherosclerosis and mortality, and that testosterone therapy has beneficial effects on multiple risk factors and risk biomarkers related to these clinical conditions.

top of page

References

1. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin. Proc. 2015;90(2):224-251.
2. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2010;95(6):2536-2559.
3. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J. Androl. 2009;30(1):1-9.
4. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur. Heart J. 2010;31(12):1494-1501.
5. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 2008;93(1):68-75.
6. Bolona ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin. Proc. 2007;82(1):20-28.
7. Corona G, Isidori AM, Buvat J, et al. Testosterone supplementation and sexual function: a meta-analysis study. The journal of sexual medicine. 2014;11(6):1577-1592.
8. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 2000;85(8):2839-2853.
9. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. The journal of sexual medicine. 2013;10(6):1612-1627.
10. Tong SF, Ng CJ, Lee BC, et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian journal of andrology. 2012;14(4):604-611.
11. Pexman-Fieth C, Behre HM, Morales A, Kan-Dobrosky N, Miller MG. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel. The aging male : the official journal of the International Society for the Study of the Aging Male. 2014;17(1):1-11.
12. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. The journal of sexual medicine. 2014;11(6):1567-1576.
13. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2010;95(2):639-650.
14. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N. Engl. J. Med. 2013;369(11):1011-1022.
15. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J. Clin. Endocrinol. Metab. 2005;90(3):1502-1510.
16. Bhasin S, Travison TG, Storer TW, et al. Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA. 2012;307(9):931-939.
17. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International journal of endocrinology. 2014;2014:683515.
18. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). 2013;21(10):1975-1981.
19. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int. J. Clin. Pract. 2014;68(3):314-329.
20. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clinical obesity. 2013;3(3-4):73-83.
21. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. The journal of sexual medicine. 2014;11(3):840-856.
22. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int. J. Impot. Res. 2008;20(4):378-387.
23. Aversa A, Bruzziches R, Francomano D, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. The aging male : the official journal of the International Society for the Study of the Aging Male. 2012;15(2):96-102.
24. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 2004;89(5):2085-2098.
25. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. (Oxf). 2001;54(6):739-750.
26. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-837.
27. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. The journal of sexual medicine. 2010;7(10):3495-3503.
28. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J. Androl. 2009;30(6):726-733.
29. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obes Res Clin Pract. 2014;8(4):e339-349.
30. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694-2701.
31. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur. J. Endocrinol. 2011;165(5):687-701.
32. Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. Am. J. Epidemiol. 2010;171(5):583-592.
33. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. J. Clin. Endocrinol. Metab. 2009;94(7):2482-2488.
34. Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J. Clin. Endocrinol. Metab. 2014;99(1):E9-18.
35. Besen J, Gan SD. A critical evaluation of clinical research study designs. J. Invest. Dermatol. 2014;134(3):e18.
36. Rohrig B, du Prel JB, Wachtlin D, Blettner M. Types of study in medical research: part 3 of a series on evaluation of scientific publications. Deutsches Arzteblatt international. 2009;106(15):262-268.
37. Vigen R, O'Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
38. Morgentaler A, Kacker R. Andrology: Testosterone and cardiovascular risk--deciphering the statistics. Nature reviews. Urology. 2014;11(3):131-132.
39. Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. The aging male : the official journal of the International Society for the Study of the Aging Male. 2014;17(2):63-65.
40. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PloS one. 2014;9(1):e85805.
41. Morgentaler A. Testosterone, cardiovascular risk, and hormonophobia. The journal of sexual medicine. 2014;11(6):1362-1366.
42. Page ST. Testosterone, cardiovascular disease, and mortality in men: living in the dark. The lancet. Diabetes & endocrinology. 2014.
43. Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! The journal of sexual medicine. 2014;11(3):624-629.
44. FDA. Citizen Petition Denial Response from FDA CDER to Public Citizen, available at http://www.regulations.gov/#!documentDetail;D=FDA-2014-P-0258-0003, accessed Aug 31, 2014.
45. Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J. Endocrinol. Invest. 2014;37:401-411.
46. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA internal medicine. 2013;173(15):1465-1466.
47. Gan EH, Pattman S, S HSP, Quinton R. A UK epidemic of testosterone prescribing, 2001-2010. Clin. Endocrinol. (Oxf). 2013;79(4):564-570.
48. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J. Clin. Endocrinol. Metab. 2014;99(3):835-842.
49. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med. J. Aust. 2012;196(10):642-645.
50. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med. J. Aust. 2013;199(8):548-551.
51. Hall SA, Araujo AB, Esche GR, et al. Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch. Intern. Med. 2008;168(10):1070-1076.
52. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract. 2006;60(7):762-769.
53. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur. Urol. 2014;65(1):115-123.
54. Moskovic DJ, Araujo AB, Lipshultz LI, Khera M. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. The journal of sexual medicine. 2013;10(2):562-569.
55. Haring R, Baumeister SE, Volzke H, et al. Prospective association of low serum total testosterone levels with health care utilization and costs in a population-based cohort of men. Int. J. Androl. 2010;33(6):800-809.
G.COM.GM.MH.05.2016.0403
top of page
Last updated: 2017
G.GM.MH.04.2015.0334